CEVA SANTE ANIMALE acquired by INSTITUT MERIEUX, SAGARD & SOFIPROTEOL
Context
Ceva announced the entry of Merieux Developpement (investment arm of Institut Merieux) into its capital, finalizing the syndicate for its fourth LBO. Merieux joins Asian investors Temasek and CDH Investments, as well as French funds Sagard, Euromezzanine, and Sofiproteol. The strategic rationale is to leverage Institut Merieux's scientific network to fight emerging diseases and antibiotic resistance, and to accelerate Ceva's expansion in Asia (China).
CEVA SANTE ANIMALE, which reported an EBITDA margin of [members only] in 2013, is valued in this transaction at an EV/EBITDA multiple of 10x–18x, representing a discount to the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Ceva is the 5th largest animal health company in the world. Headquartered in Libourne, it employs 7,000 people in 47 countries. The group balances its activity between preventive medicine (vaccines) and pharmaceutical products for poultry, swine, ruminants, and pets (30% of sales). It invests ~10% of revenue in R&D.
Ent. Value
€1–10bn
Equity Value
[members only]
Multiples
EV / Revenue
2x–6x
EV / EBITDA
10x–18x
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with CEVA SANTE ANIMALE
Other operations with CEVA SANTE ANIMALE
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 04/2025 | INSTITUT MERIEUX / ARCHIMED | CEVA SANTE ANIMALE | FRANCE | Animal Health |
| 02/2020 | TETHYS INVEST / PSP INVESTMENTS / MITSUI & CO | CEVA SANTE ANIMALE | FRANCE | Animal Health |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 11/2014 | QUALIUM | IMV TECHNOLOGIES | FRANCE | R&D Biotech |
| 11/2014 | PERRIGO COMPANY | OMEGA PHARMA | BELGIUM | Generics / Labs |
| 03/2014 | MONTAGU PRIVATE EQUITY | Arkopharma | FRANCE | Nutrition & Dietary Supplements |
| 02/2014 | MONTAGU PRIVATE EQUITY | NEMERA | FRANCE | Medical Consumables |
| 01/2014 | FIVE ARROWS | DUTSCHER | FRANCE | Medical Consumables |
| 10/2013 | ARDIAN | LABORATOIRES ANIOS | FRANCE | Medical Consumables |
| 07/2013 | CHARTERHOUSE | DOC GENERICI | ITALY | Generics / Labs |
| 06/2013 | BC PARTNERS | ANTELLIQ | FRANCE | Animal Health |
| 06/2013 | EURAZEO | PÉTERS SURGICAL | FRANCE | Medical Consumables |
| 01/2013 | ELITECH GROUP | VITAL DIAGNOSTICS | UNITED STATES | Diagnostic Equipment |
Other operations with INSTITUT MERIEUX / SAGARD / SOFIPROTEOL
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 04/2025 | INSTITUT MERIEUX / ARCHIMED | CEVA SANTE ANIMALE | FRANCE | Animal Health |
REFERENCES
Valuation range: EV €1–10bn
Revenue range: €450–900M
EBITDA range: €100–200M
EV/Revenue range: 2x - 6x
EV/EBITDA range: 10x - 18x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of CEVA SANTE ANIMALE by INSTITUT MERIEUX / SAGARD / SOFIPROTEOL are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: ceva sante animale
Acquirer: sofiproteol / sagard / institut merieux